pembrolizumab,nivolumab,ipilimumab
merck,bms
[]
one of the most impactful studies to be presented #esmo22 was the one by dr neoadjuvant approaches with io! of course, there is also the #chalabiplot 
Cancer researcher; Director of GU Cancers @DanaFarber; Prof of Medicine @HarvardMed; ? lover; ??@PanMass II Views mine.